Artificial Intelligence | April 8–10, 2019 | Boston, MA USA

Stephen Wiviott, MD

  • Executive Director, Clinical Trials Office, PHS; Associate Professor of Medicine, HMS,

Stephen D. Wiviott, MD, FACC is a graduate of University of Pennsylvania and Harvard Medical School (HMS, Honors). He served as a Medicine resident and Chief Medical Resident at Brigham and Women’s Hospital (BWH). Following his medical residency training, he served as a Cardiology fellow at Johns Hopkins Hospital. He is Associate Professor of Medicine at Harvard Medical School, and a Senior Investigator with the TIMI study group. He attends in the Lown Cardiovascular Intensive Care Unit and general Cardiology service at BWH.

As an investigator, Dr. Wiviott has played important roles in the planning, implementation, leadership, and interpretation of multicenter, national, and international clinical trials in acute coronary syndromes including the TRITON-TIMI 38 trial, PRINCIPLE-TIMI 44 and of the TIMI 38 Coronary Stent Registry. He has also served in leadership of trials of secondary prevention of cardiovascular disease as global PI of DECLARE – TIMI 58 and CAMELLIA – TIMI 61 assessing CV safety and efficacy of metabolic therapies.  He is the Chairman of the TIMI Clinical Events Committee and recognized as an expert in event definitions and adjudications.  Dr. Wiviott is an author of nearly 200 peer-reviewed publications in major medical and cardiovascular journals. He was named in 2014 and 2017 by Thomson Reuters and Clarvate Analytics as one of “The World’s Most Influential Scientific Minds” and in 2016 as a “Highly Cited Researcher,” recognitions inclusive of the top 1% of researchers in Clinical Medicine by citation.

Building on his trials experience, Dr. Wiviott was appointed Executive Director of the Clinical Trials Office (CTO) for Partners HealthCare.  The CTO provides contracting, budgeting, and clinical trial management services for Partners hospital investigators and industry sponsors and is tasked with supporting and growing clinical trials research at Partners.

This speaker's events are being finalized